DOCSLIB.ORG

Evaluation of Genetic Polymorphisms Associated with the Metabolic Effects of Aripiprazole and Olanzapine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of Genetic Polymorphisms Associated with the Metabolic Effects of Aripiprazole and Olanzapine Universidad Autónoma de Madrid Faculty of Medicine Department of Pharmacology and Therapeutics Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine Doctoral Thesis Dóra Koller 2020 Universidad Autónoma de Madrid Facultad de Medicina Departamento de Farmacología y Terapéutica Dr. Francisco Abad Santos, Jefe del Servicio de Farmacología Clínica en el Hospital Universitario de La Princesa y Profesor Titular del Departamento de Farmacología y Terapéutica de la Facultad de Medicina de la Universidad Autónoma de Madrid, CERTIFICA: Que Doña Dora Koller, ha realizado la presente Tesis Doctoral “Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine” con objeto de obtener el Grado de Doctor. Como director del trabajo hago constar que ha sido realizado con todas las garantías técnicas y metodológicas, y las conclusiones obtenidas son plenamente válidas, siendo considerado, por tanto, apto para ser presentado como Tesis Doctoral. En Madrid, a 10 de junio de 2020 Fdo. Dr. Francisco Abad Santos This thesis, submitted for the degree of Doctor of Philosophy (Ph.D.), has been elaborated in the Clinical Pharmacology Department, Instituto de Investigación Sanitaria of Hospital Universitario de La Princesa from June 2017 until June 2020 under the supervision of Dr. Francisco Abad Santos. This work was supported by the following grant: Horizon 2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant to Dóra Koller and Francisco Abad-Santos. TABLE OF CONTENTS LIST OF TABLES .................................................................................................................................... 15 LIST OF FIGURES .................................................................................................................................. 17 ABBREVIATIONS ................................................................................................................................... 20 ABSTRACT ............................................................................................................................................... 27 I. INTRODUCTION ................................................................................................................................. 37 1. CLINICAL TRIALS ................................................................................................................................... 39 2. LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY ................................................................... 41 2.1. LIQUID CHROMATOGRAPHY ................................................................................................................. 41 Components and workflow of LC ................................................................................................. 41 Analytical column and mobile phase ............................................................................................. 43 Chromatographic separation .......................................................................................................... 43 2.2. MASS SPECTROMETRY .......................................................................................................................... 43 2.3. SAMPLE PREPARATION FOR LC-MS ..................................................................................................... 46 2.4. ANALYTICAL METHOD VALIDATION .................................................................................................... 47 Selectivity ...................................................................................................................................... 47 Linearity ......................................................................................................................................... 48 LOD and LLOQ ............................................................................................................................. 48 Accuracy and precision .................................................................................................................. 48 Extraction recovery and matrix effects .......................................................................................... 48 Stability .......................................................................................................................................... 49 2.5. LC-MS IN CLINICAL PHARMACOKINETIC STUDIES ............................................................................... 49 3. PHARMACOGENETICS AND PHARMACOGENOMICS .............................................................................. 53 3.1. CONCEPT ............................................................................................................................................... 53 3.2. GENETIC POLYMORPHISMS ................................................................................................................... 54 3.3. PHARMACOGENES ................................................................................................................................. 56 Cytochrome P450 enzymes ........................................................................................................... 57 Drug transporters ........................................................................................................................... 59 3.4. CLINICAL PRACTICE GUIDELINES ........................................................................................................ 59 4. SCHIZOPHRENIA ..................................................................................................................................... 62 5. ANTIPSYCHOTIC TREATMENT ............................................................................................................... 63 5.1. ADVERSE DRUG REACTIONS ................................................................................................................. 65 5.2. OLANZAPINE ......................................................................................................................................... 68 9 Pharmacokinetics ........................................................................................................................... 68 Mechanism of action ...................................................................................................................... 69 5.3. ARIPIPRAZOLE ...................................................................................................................................... 71 Pharmacokinetics ........................................................................................................................... 71 Mechanism of action ...................................................................................................................... 72 5.4. ADVERSE DRUG REACTIONS TO ARIPIPRAZOLE AND OLANZAPINE ...................................................... 74 6. PUPILLOMETRY ...................................................................................................................................... 76 7. THE PHARMACOGENETICS OF ARIPIPRAZOLE AND OLANZAPINE ...................................................... 78 7.1. GENES RELATED TO PHARMACOKINETICS ............................................................................................ 78 7.2. GENES RELATED TO PHARMACODYNAMICS ......................................................................................... 82 II. OBJECTIVES ...................................................................................................................................... 87 III. MATERIALS AND METHODS ....................................................................................................... 91 1. CLINICAL TRIAL ..................................................................................................................................... 93 1.1. STUDY DESIGN ...................................................................................................................................... 93 1.2. STUDY POPULATION ............................................................................................................................. 93 1.3. PROCEDURES ........................................................................................................................................ 95 Sample collection for pharmacokinetic analysis ........................................................................... 95 Biochemical and haematological analyses .................................................................................... 98 Analysis of blood pressure and electrocardiogram ........................................................................ 98 Safety and tolerability assessments ................................................................................................ 99 Pupillometric measurements .......................................................................................................... 99 2. ANALYTICAL METHOD VALIDATION ................................................................................................... 100 2.1. CHEMICALS AND REAGENTS .............................................................................................................. 100 2.2. PREPARATION OF CALIBRATION STANDARDS AND QUALITY CONTROLS ........................................... 101 2.3. EQUIPMENT ........................................................................................................................................
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,642,801 B2 Sesha (45) Date of Patent: May 9, 2017
    USOO96428O1B2 (12) United States Patent (10) Patent No.: US 9,642,801 B2 Sesha (45) Date of Patent: May 9, 2017 (54) AND POTENT TAPENTADOL DOSAGE 5,866,164 A 2/1999 Kuczynski et al. FORMS 6,103.258 A 8, 2000 Simon 6,228,863 B1 5, 2001 Palermo et al. 6,248,737 B1 6/2001 Buschmann et al. (75) Inventor: Ramesh Sesha, Windsor, NJ (US) 6,277.384 B1 8, 2001 Kaiko et al. 6,309.668 B1 10/2001 Bastin et al. (73) Assignee: Gruenenthal GmbH, Aachen (DE) 6,375,957 B1 4/2002 Kaiko et al. 6,475,494 B2 11/2002 Kaiko et al. (*) Notice: Subject to any disclaimer, the term of this 6,559,159 B2 5/2003 Carroll et al. 6,696,066 B2 2/2004 Kaiko et al. patent is extended or adjusted under 35 6,696,088 B2 2/2004 OShlack et al. U.S.C. 154(b) by 184 days. 6,716,449 B2 4/2004 OShlack 6,765,010 B2 7/2004 Crain et al. (21) Appl. No.: 13/091,871 RE39,593 E 4/2007 Buschmann et al. 7,332,142 B2 2/2008 Telford et al. (22) Filed: Apr. 21, 2011 7,658,939 B2 2/2010 Oshlack et al. 7.682,632 B2 3/2010 Oshlack et al. O O 7,718,192 B2 5/2010 Oshlack et al. (65) Prior Publication Data 7,842,309 B2 11/2010 Oshlack et al. US 2011 FO28.1855A1 Nov. 17, 2011 7,842,311 B2 11/2010 Oshlack et al.
    [Show full text]
  • ES 2 357 355 T3 Venta De Fascículos: Oficina Española De Patentes Y Marcas
    11 Número de publicación: 2 357 355 19 OFICINA ESPAÑOLA DE PATENTES Y MARCAS 51 Int. Cl.: A61K 31/135 (2006.01) (2006.01) ESPAÑA A61P 19/02 A61P 25/04 (2006.01) 12 TRADUCCIÓN DE PATENTE EUROPEA T3 96 Número de solicitud europea: 08758440 .5 96 Fecha de presentación : 09.05.2008 97 Número de publicación de la solicitud: 2155179 97 Fecha de publicación de la solicitud: 24.02.2010 54 Título: Axomadol para el tratamiento del dolor en caso de artrosis. 30 Prioridad: 11.05.2007 DE 10 2007 022 790 73 Titular/es: GRÜNENTHAL GmbH Zieglerstrasse 6 52078 Aachen, DE 45 Fecha de publicación de la mención BOPI: 72 Inventor/es: Schiene, Klaus; 25.04.2011 Bloms-Funke, Petra; Bothmer, John y Lefeber, Claudia 45 Fecha de la publicación del folleto de la patente: 74 Agente: Aznárez Urbieta, Pablo 25.04.2011 Aviso: En el plazo de nueve meses a contar desde la fecha de publicación en el Boletín europeo de patentes, de la mención de concesión de la patente europea, cualquier persona podrá oponerse ante la Oficina Europea de Patentes a la patente concedida. La oposición deberá formularse por escrito y estar motivada; sólo se considerará como formulada una vez que se haya realizado el pago de la tasa de oposición (art. 99.1 del Convenio sobre concesión de Patentes Europeas). ES 2 357 355 T3 Venta de fascículos: Oficina Española de Patentes y Marcas. Pº de la Castellana, 75 – 28071 Madrid ES 2 357 355 T3 DESCRIPCIÓN Axomadol para el tratamiento del dolor en caso de artrosis La invención se refiere a la utilización de axomadol para el tratamiento del dolor en caso de artrosis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,133,269 B2 Mcconnell Et Al
    USOO9133269B2 (12) United States Patent (10) Patent No.: US 9,133,269 B2 McConnell et al. (45) Date of Patent: Sep. 15, 2015 (54) HUMANIZED ANTIBODIES DIRECTED Carter, Nature Reviews Immunol 6, 343-357 (2006). AGAINST COMPLEMENT PROTEIN CS Copland et al., Clinical and Experimental Immunol. 159: 303-314 (2010). Dmytrijuk et al., The Oncologist, 13(9): 993-1000 (2008). (71) Applicant: ANAPTYSBIO, INC., San Diego, CA Gilles et al., BMC Genomics 12, 245 (2011). (US) Glanville et al., Proc. Natl. Acad. Sci. USA 106,20216-20221 (2009). Goldstein et al., New Engl. J. Med. 313, 337-342 (1985). 72). I nventors: Audrey McCMcConnell, l, San Diego, CA Ho et al., Gene 77, 51-59 (1989). (US); Peter M. Bowers, San Diego, CA Hoet et al., Nature Biotechnology 23, 344-348 (2005). (US); David J. King, Encinitas, CA (US) Hoogenboom, Nature Biotechnology 23, 1105-1116 (2005). Kaplan, Curr. Opin. Investig. Drugs, 3: 1017-1023 (2002). (73) Assignee: AnaptysBio, Inc., San Diego, CA (US) Kasper et al., Current Medical Research and Opinion 22, 1671-1678 (2006). (*) Notice: Subject to any disclaimer, the term of this Knappik et al., Journal of Molecular Biology 296, 57-86 (2000). patent is extended or adjusted under 35 Koboldt et al., Bioinformatics (Oxford, England) 25, 2283-2285 U.S.C. 154(b) by 0 days. (2009). Kohler, Nature 256,495-497 (1975). Lonberg, Nature Biotechnology 23, 1117-1125 (2005). (21) Appl. No.: 13/972.524 Mahaffey et al., Circulation, 108: 1176-1183 (2003). Martin et al., Am J Reprod Immunol 58, 138-149 (2007). (22) Filed: Aug.
    [Show full text]
  • Page | 1 Tuesday June 10 18.30-20.00 Registration at The
    Tuesday June 10 18.30-20.00 Registration at the Cruise Terminal 20.30-22.30 Welcome reception at the Santísima Trinidad located in front of Hotel Melia Wednesday June 11 08:00-08:45 Registration 08:45-09:00 Welcome and Introduction Chair: Leon Aarons and Panos 09:00-10:20 OrBiTo and Mechanistic absorption modelling Macheras Amin Rostami- OrBiTo - translating mechanistic knowledge on absorption into predictive 09:00-09:40 Hodjegan models Benjamin Mechanism-based modelling of gastric emptying and bile release in response 09:40-10:00 Guiastrennec to caloric intake Andrés An in silico physiologically-based pharmacokinetic (PBPK) study of the impact 10:00-10:20 Olivares- of the drug release rate on oral absorption, gut wall metabolism and relative Morales bioavailability 10:20-11:50 Coffee break, Poster and Software session I Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 11:50-12:40 Facilitating Modelling and Simulation Chair: Charlotte Kloft Development of Virtual Population for a Quantitative Systems Pharmacology 11:50-12:10 Kapil Gadkar model 12:10-12:30 Maciej Swat PharmML 1.0 – An Exchange Standard for Models in Pharmacometrics Marc 12:30-12:40 Proposal for a Web-Based Open Pharmacometrics Curriculum Gastonguay 12:40-14:10 Lunch 14:10-15:10 Model-based individualisation Chair: Nick Holford Pierre 14:10-14:50 Implementing model-based individualization in the clinic Marquet Page | 1 Núria Buil A step forward toward personalised medicine in oncology: Population 14:50-15:10 Bruna modelling for
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) (Rev
    Harmonized Tariff Schedule of the United States (2011) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]